Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Initial safety and efficacy data from fadraciclib monotherapy in patients with advanced solid tumors preselected for CDKN2A and/or CDKN2B abnormalitiesBERKELEY HEIGHTS, N.J., Oct. 09, 2024 (GLOBE ...
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Patients are preselected for CDKN2A and/or CDKN2B abnormalities -- Safety and efficacy data to be reported at an upcoming oncology medical ...
precisionmedicineonline7h
Bluebird Bio's Skysona Gene Therapy Benefits Patients Years Later, But Some Develop Blood Cancer
Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases ...
News Medical on MSN3d
Researchers uncover how senescent cells can both harm and heal in liver disease
By Vijay Kumar Malesu New genetic tools reveal the dual roles of senescent cells in liver disease—macrophages drive fibrosis, ...
Nature11y
The p53 and RB tumour-suppressor pathways
In the p53 pathway, signals such as DNA damage induce the ARF (also known as p14 in humans and p19 in mice) product of the CDKN2A locus. ARF increases p53 levels by sequestering MDM2, which ...
The EMBO Journal11d
Cellular senescence, p21, and the path to fibrosis
In this issue, Papismadov et al (2024) report that p21 (CDKN1A), known to activate the senescence growth arrest, also ...
Nasdaq16d
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
“We are pleased to report that the Cyclacel team has achieved another important milestone by completing enrollment of the patient cohort with CDKN2A/B abnormalities,” said Spiro ...